Biotech Values

[mcbio]

ASMB -

What is the real reason for the exclusion? Maybe that they don't yet know what dose to use in e-antigen- patients, based on the flattish dose-response curve in phase-1.

I think part of the reason for the flattish curve is due to the one patient that had the CpAM-resistant mutation and then the other two were thought to have the possible compliance issues. But, you're right, there's no reason we should expect these issues to be limited to e-antigen- patients and thus a reason to exclude them from a future trial. So, there could be an unknown reason why ASMB plans to exclude this group.

It will be interesting to see how the market reacts if ASMB is able to deliver on the P2a data next year in the e-antigen+ patients.